EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1 / PD‐L1 blockade response in urothelial carcinoma

Kaifeng Jin, Jingtong Xu, Xiaohe Su, Ziyue Xu, Bingyu Li, Ge Liu, Hailong Liu, Yiwei Wang, Yu Zhu, Le Xu, Weijuan Zhang, Zhaopei Liu und 3 weitere

The Journal of Pathology · 2024-06 · 263 (2) · 139-149

DOI: 10.1002/path.6266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, online erschienen am 21.02.2024. Verfasst von Kaifeng Jin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, PR China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Mutation, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Sailing Program, Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 mutation is one of the most common genetic alterations in urothelial carcinoma (UrCa), and heterogeneity of TP53 mutants leads to heterogeneous clinical outcomes. This study aimed to investigate the clinical relevance of specific TP53 mutations in UrCa. In this study, a total of eight cohorts were enrolled, along with matched clinical annotation. TP53 mutations were classified as disruptive and nondisruptive according to the degree of disturbance of p53 protein function and structure. We evaluated the clinical significance of TP53 mutations in our local datasets and publicly available datasets. The co‐occurring events of TP53 mutations in UrCa, along with their therapeutic indications, functional effects, and the tumor immune microenvironment, were also investigated. TP53 mutations were identified in 49.7% of the UrCa patients. Within this group, 25.1% of patients carried TP53 Disruptive mutations, a genetic alteration correlated with a significantly poorer overall survival (OS) when compared to individuals with TP53 Nondisruptive mutations and those with wild‐type TP53 . Significantly, patients with TP53 Disruptive mutations exhibit an increased probability of responding favorably to PD‐1/PD‐L1 blockade and chemoimmunotherapy. Meanwhile, there was no noteworthy distinction in OS among patients with varying TP53 mutation status who underwent chemotherapy. Samples with TP53 Disruptive mutations showed an enriched APOBEC‐ and POLE‐related mutational signature, as well as an elevated tumor mutation burden. The sensitivity to immunotherapy in tumors carrying TP53 Disruptive mutation may be attributed to the inflamed tumor microenvironment characterized by increased CD8 + T cell infiltration and interferon‐gamma signaling activation. In conclusion, UrCa patients with TP53 Disruptive mutations have shown reduced survival rates, yet they may respond well to PD‐1/PD‐L1 blockade therapy and chemoimmunotherapy. By distinguishing specific TP53 mutations, we can improve risk stratification and offer personalized genomics‐guided therapy to UrCa patients. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53MutationImmune Checkpoint InhibitorsB7-H1 AntigenTumor MicroenvironmentProgrammed Cell Death 1 ReceptorUrinary Bladder NeoplasmsHumansCarcinoma, Transitional CellBiomarkers, TumorMaleFemaleAntineoplastic Combined Chemotherapy ProtocolsAgedMiddle Aged

Stichwörter der Autor:innen

PD‐1/PD‐L1 blockadeTP53 mutationschemoimmunotherapyplatinum‐based chemotherapyurothelial carcinoma

Substanzen

Tumor Suppressor Protein p53Immune Checkpoint InhibitorsCD274 protein, humanB7-H1 AntigenTP53 protein, humanProgrammed Cell Death 1 ReceptorPDCD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
  • NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
  • Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
  • Department of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
  • Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
  • Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, PR China.

ORCID-Profile: Jiejie Xu

Förderung

  • Shanghai Sailing Program
  • Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation
  • National Natural Science Foundation of China
  • Shanghai Municipal Natural Science Foundation
  • China Postdoctoral Science Foundation
  • Shanghai Anticancer Association EYAS PROJECT
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Jin, K., Xu, J., Su, X., Xu, Z., Li, B., Liu, G., Liu, H., Wang, Y., Zhu, Y., Xu, L., Zhang, W., Liu, Z., Wang, Z., Chang, Y., & Xu, J. (2024). TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1 / PD‐L1 blockade response in urothelial carcinoma. The Journal of Pathology, 263(2), 139-149. https://doi.org/10.1002/path.6266

Vancouver

Jin K, Xu J, Su X, Xu Z, Li B, Liu G, et al. TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1 / PD‐L1 blockade response in urothelial carcinoma. The Journal of Pathology. 2024;263(2):139-149. doi:10.1002/path.6266

BibTeX
@article{Jin2024,
  author = {Jin, Kaifeng and Xu, Jingtong and Su, Xiaohe and Xu, Ziyue and Li, Bingyu and Liu, Ge and Liu, Hailong and Wang, Yiwei and Zhu, Yu and Xu, Le and Zhang, Weijuan and Liu, Zhaopei and Wang, Zewei and Chang, Yuan and Xu, Jiejie},
  title = {TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1 / PD‐L1 blockade response in urothelial carcinoma},
  journal = {The Journal of Pathology},
  year = {2024},
  volume = {263},
  number = {2},
  pages = {139--149},
  doi = {10.1002/path.6266}
}
Kostenlos starten →